<code id='3409774542'></code><style id='3409774542'></style>
    • <acronym id='3409774542'></acronym>
      <center id='3409774542'><center id='3409774542'><tfoot id='3409774542'></tfoot></center><abbr id='3409774542'><dir id='3409774542'><tfoot id='3409774542'></tfoot><noframes id='3409774542'>

    • <optgroup id='3409774542'><strike id='3409774542'><sup id='3409774542'></sup></strike><code id='3409774542'></code></optgroup>
        1. <b id='3409774542'><label id='3409774542'><select id='3409774542'><dt id='3409774542'><span id='3409774542'></span></dt></select></label></b><u id='3409774542'></u>
          <i id='3409774542'><strike id='3409774542'><tt id='3409774542'><pre id='3409774542'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          entertainment

          author:Wikipedia    - browse:116
          Alnylam headquarters
          Kristoffer Tripplaar/Sipa USA/AP

          A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

          The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

          advertisement

          “It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia